Cell Culturing Pre-Summit Workshop

• As the cell-based ecosystem continue to evolve will one model succeed over another, or will diversification strengthen the sector holistically?
• End-to-end solutions have dominated the cell-based market, but how are cell-based supply chains evolving with pick-and-shovel models, and what impact does this have?
• What exciting developments have been made with growth media & scaffolding technologies?
• With an increase of hybrid technologies combining cell and plant-based ingredients entering the space, what will the future of the cell based market look like and what exciting new products might emerge?

Speakers:
Romy M. Dalton, COO, COCOON BIOSCIENCE
Kevin Benmoussa, CFO, ALEPH FARMS
Patricia Bubner, CEO & Founder, ORBILLION BIO

• Scaling is CAPEX intensive, and in times of economic instability, what type of partnerships could provide opportunity for innovators to reach scale and proof of concept but at lower cost?
• Partnerships are crucial for progress across the value chain, how can new start-ups create a holistic business strategy to include open innovation and strategic partnerships?
• What role do CDMOs play in partnerships with innovators to enable scale and what is truly required in order to scale? What does successful collaboration look like?

Speaker:
Steve Thomas, Associate Director Applied Science and Industrial Biotechnology, CAMBRIDGE CONSULTANTS

In this session, delegates will break out into groups and work together to discuss potential solutions to a pressing industry problem. Each group will then present their findings at the end.

Host:
Steve Thomas, Associate Director Applied Science and Industrial Biotechnology, CAMBRIDGE CONSULTANTS

• As the market grows, how do new companies find their niche, reach commercialization without market saturation, and how role does IP & patenting play to achieve this?
• How important are IP & patents to establish differentiation between products as more companies reach the point of scale-up, and in turn help to improve consumer messaging and understanding?
• Does intellectual property act as a pathway or roadblock to scale? Does it encourage competition within the alt-protein category, or with the conventional foods intended?
• What precedent does the recent lawsuit with Impossible & Motif set for the food industry and patenting, what are learnings for others in the space and what are the impacts?

Speaker:
Ian Schmertzler, CEO, DISPEL

• With the recent historic approval for cell-cultivated meat in the USA, what does this mean for the future of cell-based foods?
• What impact will approvals have on the challenge of scale – will it be a gateway to funding for high CapEx facilities and scaling activities, or will approvals stall?
• What’s the best practice to achieve regulatory approval? How can innovators best engage with regulators and weave food safety into strategy, in order to reach approval?
• Both Singapore and the US have seen approvals, but what’s happening around the globe? Is there a need for a holistic approach to regulation for cell-based products?

• How do the challenges for the plant-based space in 2022 foreshadow the path of other novel foods, including cell based? What are the drivers around this blip, and how can cell-based prevent this?
• What does this say about consumer adoption of new foods, and what should cell-based focused companies learn from this around the key drivers of nutritional profile, taste, texture & price?
• What role can education, branding & messaging play in consumer adoption? How can innovators communicate the technicality of cell-based foods without alienating the consumer, and overcoming the drive for ‘natural’?

Hosted by: